A new clinical study is currently recruiting participants to assess the effectiveness of irreversible electroporation (IRE) ablation in treating recurrent or metastatic cervical lymph node metastases resulting from thyroid cancer. This prospective multicenter, single-arm study is sponsored by Tian’an Jiang and represents a significant step in advancing therapeutic options for these challenging conditions.
What is Irreversible Electroporation?
Irreversible electroporation (IRE) is a non-thermal ablation technique that uses electrical pulses to create irreversible pores in cellular membranes. Unlike thermal methods, IRE targets tissue with precision, causing minimal damage to surrounding structures such as blood vessels, nerves, or ducts. This characteristic makes it a promising option for treating challenging tumor locations, including cervical lymph node metastases from thyroid cancer.
Study Objectives and Scope
The study aims to evaluate the safety, efficacy, and feasibility of using IRE devices to treat specific patients diagnosed with recurrent or metastatic lymph node metastases originating from thyroid cancer. Conducted across multiple centers, this single-arm trial will provide robust data on the device’s therapeutic potential. If successful, this clinical research could pave the way for regulatory approval, offering a cutting-edge solution for patients with limited conventional treatment options.
This trial highlights the growing interest in innovative device-based solutions for cancer therapy, reinforcing a trend in medical device development aimed at improving clinical outcomes while maintaining safety and precision.
Who Can Participate?
The study is recruiting individuals diagnosed with thyroid cancer who also exhibit cervical lymph node metastases. Eligible participants must meet specific inclusion and exclusion criteria, which are designed to ensure the safety and validity of the study results. The criteria likely include factors such as disease stage, overall health condition, and prior treatments undergone.
This trial offers an opportunity for eligible patients to access state-of-the-art treatment while contributing to advancing cancer care research.
Frequently Asked Questions
- What is the goal of this clinical trial?
The trial aims to evaluate the use of IRE ablation devices for the treatment of cervical lymph node metastases derived from thyroid cancer. - Is the study currently recruiting participants?
Yes, the status indicates the study is actively recruiting participants. - How does IRE differ from other ablation techniques?
Unlike thermal methods, IRE uses electrical pulses to target cellular membranes without heating, minimizing collateral tissue damage. - Where can I find more information?
Additional details are available at the ClinicalTrials.gov link provided below.
Conclusion
This study showcases the potential of irreversible electroporation to address complex cases of thyroid cancer metastases. Healthcare professionals, clinical researchers, and regulatory teams should monitor its outcomes for valuable insights into device-based therapeutic advancements. Eligible patients are encouraged to discuss participation with their treating physicians.
Disclaimer
This article is for informational purposes only and does not constitute legal, clinical, or regulatory advice. Please consult appropriate professionals for specific guidance.
Announcement Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07328243?term=medical+device